Noemi Michetti
Overview
Explore the profile of Noemi Michetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giancola R, Oliva F, Gallorini M, Michetti N, Gissi C, Moussa F, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499497
Rotator cuff tendon (RCT) disease results from multifactorial mechanisms, in which inflammation plays a key role. Pro-inflammatory cytokines and tendon stem cell/progenitor cells (TSPCs) have been shown to participate in...
2.
Cecchetti L, Tolley N, Michetti N, Bury L, Weyrich A, Gresele P
Blood
. 2011 Jun;
118(7):1903-11.
PMID: 21628401
Megakaryocytes transfer a diverse and functional transcriptome to platelets during the final stages of thrombopoiesis. In platelets, these transcripts reflect the expression of their corresponding proteins and, in some cases,...
3.
Schwertz H, Koster S, Kahr W, Michetti N, Kraemer B, Weitz D, et al.
Blood
. 2010 Jan;
115(18):3801-9.
PMID: 20086251
Platelets are classified as terminally differentiated cells that are incapable of cellular division. However, we observe that anucleate human platelets, either maintained in suspension culture or captured in microdrops, give...
4.
Greinacher A, Fuerll B, Zinke H, Mullejans B, Kruger W, Michetti N, et al.
Blood
. 2009 May;
114(6):1250-3.
PMID: 19429867
Glycoprotein (GP) IIbIIIa inhibitors are used in the treatment of acute coronary syndromes. Transient immune-mediated acute thrombocytopenia is a recognized side effect of GPIIbIIIa inhibitors. We provide evidence that GPIIbIIIa...
5.
Foulks J, Marathe G, Michetti N, Stafforini D, Zimmerman G, McIntyre T, et al.
Blood
. 2009 Apr;
113(26):6699-706.
PMID: 19395675
Platelet activating factor (PAF) and PAF-like lipids induce inflammatory responses in target cells. These lipid mediators are inactivated by PAF-acetylhydrolase (PAF-AH). The PAF signaling system affects the growth of hematopoietic...
6.
Ferroni P, Guagnano M, Falco A, Paoletti V, Manigrasso M, Michetti N, et al.
Clin Sci (Lond)
. 2007 Nov;
114(6):449-55.
PMID: 17988217
Increased levels of sCD40L (soluble CD40 ligand) have been associated with enhanced in vivo platelet activation, and may represent a molecular link between inflammation and a prothrombotic state. The aim...
7.
Formoso G, De Filippis E, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, et al.
Diabetes Metab Res Rev
. 2007 Oct;
24(3):231-7.
PMID: 17966969
Background: In type 2 diabetes, metformin reduces cardiovascular risk beyond the effect of glycaemic control. Since oxidative stress and the consequent enhanced platelet activation contribute to accelerated atherosclerosis in diabetes,...
8.
Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, et al.
Free Radic Biol Med
. 2007 Jul;
43(4):511-8.
PMID: 17640561
Advanced glycation end products (AGEs) contribute to diabetic vascular complications by engaging the AGE receptor (RAGE). A soluble RAGE form (sRAGE) acts as a decoy domain receptor, thus decreasing AGE...